Aptose Biosciences Acquisition by Hanmi Pharmaceutical Finalized; Delisting Imminent
APTOF has more than doubled off its 52-week low of $0.636 on light trading volume (0.1× avg).
Summary
Aptose Biosciences has finalized its acquisition by Hanmi Pharmaceutical, with shareholders receiving C$2.41 cash per share. This resolution follows earlier reports of Aptose's significant financial distress and previous delays in the acquisition process. As a result, Aptose will cease to be an independent public entity, and its shares are expected to be delisted from the TSX around July 3, 2026. The company will also terminate its public reporting requirements.
At the time of this announcement, APTOF was trading at $1.62 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.64 to $1.89. This news item was assessed with neutral market sentiment and an importance score of 10 out of 10. Source: GlobeNewswire.